




2016/2017 GSK Seasonal Influenza Portfolio Update 

Influenza vaccines: Fluarix® Quadrivalent and FluLaval® Quadrivalent

We are on track to deliver our commitment to influenza programs




- GSK continues to prioritize influenza immunization
- All Seasonal doses will be Quadrivalent Influenza vaccine.
- Expanded our Influenza network and increased global capacity for Pre-Filled Syringes (PFS)

NAIIS 2016 2

Continued focus on evolving solutions to cover US Influenza recommendations*



Leading development



NAISS 2016
* Portfolio completed by end of 2016 (expected).

Shifting the paradigm for influenza prevention



Evolving in a Multi-stakeholder community

- Ability to supply the market ✓
- Addressing apathy toward influenza immunization
- Continue to build on Access and Convenience to increase immunization rates



NAISS 2016